Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/200869
MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Elucidating the adaptive mechanisms that prevent host immune response in cancer will help predict efficacy of anti-programmed death-1 (PD1)/L1 therapies. Here, we study the cell-intrinsic response of lung cancer (LC) to interferon-y (IFNy), a cytokine that promotes immunoresponse and modulates programmed death-ligand 1 (PD-L1) levels. We report complete refractoriness to IFNy in a subset of LCs as a result of JAK2 or IFNGR1 inactivation. A submaximal response affects another subset that shows constitutive low levels of IFNy-stimulated genes (IySGs) coupled with decreased H3K27ac (histone 3 acetylation at lysine 27) depo-sition and promoter hypermethylation and reduced IFN regulatory factor 1 (IRF1) recruitment to the DNA on IFNy stimulation. Most of these are neuroendocrine small cell LCs (SCLCs) with oncogenic MYC/MYCL1/ MYCN. The oncogenic activation of MYC in SCLC cells downregulates JAK2 and impairs IySGs stimulation by IFNy. MYC amplification tends to associate with a worse response to anti-PD1/L1 therapies. Hence alterations affecting the JAK/STAT pathway and MYC activation prevent stimulation by IFNy and may predict anti-PD1/L1 efficacy in LC.
Matèries
Matèries (anglès)
Citació
Citació
ALBURQUERQUE BEJAR, Juan j., NAVAJAS CHOCARRO, Pablo, SAIGÍ, Maria, FERRERO ANDRÉS, Ana, MORILLAS, Juan m., VILARRUBI PORTA, Andrea, GOMEZ, Antonio, MATE, José l., MUNOZ MARMOL, Ana m., ROMERO FERRARO, Octavio, BLECUA, Pedro, DAVALOS, Veronica, ESTELLER, Manel, PROS, Eva, LLABATA, Paula, TORRES DIZ, Manuel, ESTEVE CODINA, Anna, SÁNCHEZ CÉSPEDES, Montserrat. MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer. _Cell Reports Medicine_. 2023. Vol. 4, núm. 4, pàgs. 101006. [consulta: 20 de gener de 2026]. ISSN: 2666-3791. [Disponible a: https://hdl.handle.net/2445/200869]